A double-digit coupon looks like a reward, yet the risks of structured products usually hide behind that very number. More often, a generous rate is a warning, not a gift.
The danger rarely sits in the headline rate; it sits in the barrier level, the estimated value, and the single issuer behind every promise. If you are weighing one, start from the losses, not the brochure, keeping the broader picture of understanding structured products in view. You were sold the upside and handed no map of the downside, and that map is where an honest assessment begins.
You were shown a payoff diagram and a coupon, never the loss map, and that gap is where the trouble starts.
A structured product is a package: a bond that aims to return your capital, wrapped around a derivative that delivers the payoff, engineered to a specific outcome and sold to you as one security. Every risk that follows traces back to one of those two parts.
Most carry no guaranteed principal protection, so a poor run in the reference asset can cost you some, or all, of your money. It does not fail in one tidy way; it erodes capital through several mechanisms, each worth its own look.
“Is it safe?” is the wrong question. Ask three sharper ones: how far can this fall before I lose capital, can I exit before maturity, and do I understand how the payoff is built?
Here is the whole map before the deep dives, each category with its own way of costing you capital and its own check.
| Risk category | How you lose capital | What to check first |
|---|---|---|
| Market and barrier breach | A fall past a protection level exposes you to loss from the strike | The barrier or buffer level, and the underlying's volatility |
| Liquidity and valuation | No real secondary market can leave you unable to exit near fair value | Whether the issuer will quote a buy-back, and the estimated value |
| Complexity and opacity | A payoff you cannot model is a risk you cannot price | That you can explain the caps, participation and knock-in yourself |
| Regulatory and suitability | A mis-sold or mis-classified product may not fit your capacity for loss | Your client classification and the target market in the KID |
| Concentration | Stacking products on one issuer turns a single event into a portfolio loss | Total exposure to that issuer and to shared underlyings |
One exposure runs beneath all five. At its core a structured product is a debt claim on the institution that issued it, an unsecured obligation whose every promise is only as sound as that issuer's finances. If the issuer cannot pay, the cleverest payoff returns nothing. The counterparty discipline that governs private credit risk, sizing who you lend to before the yield, applies directly here.
The risk of a structured product is not one thing but five: market and barrier breach, liquidity, complexity, suitability and concentration. Each erodes capital in its own way, and each needs its own check before you buy.
Most losses begin at one level: the barrier. The common mistake is treating a barrier and a buffer as the same thing; they are not, and the difference decides how much you lose.
The upside pays for the trade. Your upside is capped while the downside is not, so even a strong rally in the reference asset returns only the ceiling the note sets.
Two things the coupon hides. A generous coupon is not a gift; it is the market charging you for more risk, a tighter barrier, a more volatile underlying, or a weaker issuer. The strike is usually fixed on one observation date, so a poor fixing disadvantages the whole payoff for its life. Sharpest is a worst-of note, whose payoff tracks the single weakest asset in a basket and can hand you losses unconnected to the market.
Structured products are built to be held to maturity, and that design carries a cost. There is often no genuine secondary market: liquidity is frequently very limited, the only realistic buyer may be the issuer or distributor, and issuers often disclaim any duty to make one. Even when a buyer exists, a customised payoff can be quoted, per FINRA (2023), at a significant discount to face value.
The deeper problem is not the exit; it is day one. The price you pay sits above the issuer's disclosed estimated value by a structural margin (selling, structuring and hedging costs), present on every product and amortised against you over the note's life, whether you sell or not.
The day-one value gap is built-in and non-recoverable, not a sell-early surcharge, so a note can be worth less than you paid even while the underlying is up.
Every wealth journey starts with a conversation. Our advisers are ready to understand your objectives, assess your circumstances, and build a strategy tailored to your goals.
Begin Your Journey With UsComplexity is not an inconvenience you can read around; it is a risk transferred to you. The conflict is plain: the same institution designs the product, prices it, sells it, and later quotes your exit price. A complex product is one whose features make it hard for a retail investor to grasp how it behaves.
Disclosure often makes this worse. The FCA (2026) flags firms that lean solely on the manufacturer's key information document without explaining leverage, volatility and spreads. The correction that matters most concerns the KID's performance scenarios: they are pro-cyclical, extrapolating recent calm and reading optimistically.
Read the KID against the grain:
The same institution designs, prices, sells and later values the product. Its performance scenarios read optimistically in calm markets, so the stress line and the cost summary are the only figures worth trusting.
Suitability lives here too. In the DIFC, the DFSA (2018) has made investor protection a high priority and criticised tick-box assessments that record a preference without testing it; in the US, recommending one invites a Regulation Best Interest review. The usage data exposes the mismatch: the FCA (2026) found 82% of 531,007 complex exchange-traded product trades held beyond the recommended one-day period, with such trading up 23% year on year and only around 70% of buyers passing the appropriateness test first time.
UK use of non-advised platforms nearly doubled from 5.9% of adults in 2020 to 11% in 2024 (FCA, 2026), putting complex products a click from buyers who face no suitability check.
Whether a structured product is a good investment depends on what it replaces and what you surrender. The benefits are real: FINRA (2023) notes they are engineered for defined goals, growth, income or risk management, and they can give access to payoffs a private investor could not build alone.
Each benefit carries a price; hold the two side by side.
| The benefit you are sold | What it actually costs you |
|---|---|
| Enhanced or defined coupon | Capped upside, and a coupon that prices in real risk |
| Downside buffer or barrier | Protection only to a point, lost once breached |
| Capital protection | Maturity only, in nominal terms, if the issuer survives |
| Tailored market access | Embedded fees, and the underlying's dividends forgone |
| A known outcome | Reinvestment risk if an autocall ends it early |
Two claims need correcting. Capital protection is not clean safety: it holds only at maturity, it is nominal not inflation-adjusted, and it rests on the issuer staying solvent. And the claim that structured products outperform their underlying does not survive a fair-value and lost-dividend adjustment; against true cost, the edge disappears.
The hidden costs compound. FINRA (2023) points out that you can tie up capital for a decade, inflation eroding it, with no profit to show, while forgone dividends and caps drain the return. In some jurisdictions a note even triggers tax on income you have not yet received.
Demand still persists, and the SRP (2025) survey ties it to the end of ultra-low rates reviving attractively priced protected notes. Set against other alternative investment risks, the trade-off is neither uniquely good nor bad; it is one you must be able to price before you buy.
Everyone says read the KID. Few say what to check. Before you commit, run this list.
These are the questions to ask before buying, down to the plainest: do I actually understand this? Then size it: cap the allocation, spread it across issuers, match each maturity to a liquidity need, prefer one clean index over a worst-of basket, and price in the dividends you forgo.
Concentration is where failures multiply. Investors have lost significant portions of their portfolios by stacking complex products on one issuer or overlapping baskets, so a single move becomes a portfolio event.
How often do the triggers fire? The SRP (2025) survey offers rare perspective: of the products it tracked, only 72 breached their defensive barriers and just 196 of 786 autocalls missed an eligible date, useful for sizing real downside without complacency or panic. In the DIFC, you can also ask to be classified as a Retail Client, with proper suitability documentation.
.jpg)
They fall into five categories: market and barrier breach, liquidity and valuation, complexity and opacity, regulatory and suitability, and concentration. Each can cost you capital differently, from a breached barrier to an exit you cannot make near fair value.
It depends on what the product replaces and what you give up: capped upside, embedded fees, forgone dividends and a long lock-up. The benefits are real, but worth it only once you have priced that cost. Contact us for more information.
Often not easily. They are built to be held to maturity, and there is frequently no real secondary market. The only buyer may be the issuer or distributor, who need not quote a price, so selling early can mean a steep discount.
“Safe” is the wrong test. Ask how far it can fall before you lose capital, whether you can exit before maturity, and whether you understand the payoff. Those three answers, not a label, are the real risk. Begin your journey with us.
No. Protection holds only at maturity, is nominal so inflation erodes it, and depends on the issuer staying solvent. It also caps your upside, trading gains for conditional, not absolute, safety.
This guide is provided for general information purposes only and does not constitute financial advice. Structured products are complex instruments whose returns and risks depend on individual circumstances, and past performance does not guarantee future results. Consider professional advice before making any investment decision.
